Introduction Substance use disorders (SUDs) are a prevalent issue in the United States (U.S.) and there is a need for innovative treatments to address this public health issue. As of March 2025, there are seven states either approved or in the process of applying for Sect. 1115 Demonstration Waivers to implement pilot contingency management (CM) programs for SUD treatment. This manuscript qualitatively summarizes these Sect. 1115 Demonstration Waivers and the different aspects of each U.S. state's program. Methods Data are from states Sect. 1115 Demonstration Waivers, collected through September 2024 and updated in March 2025. When possible the information has been verified with pilot program managers from each state, and pilot program managers have provided information when possible. Results Eight states have applied for Sect. 1115 Demonstration Waivers to implement pilot CM programs. Five states have been approved (California, Washington, Montana, Hawaii, and Delaware), two are pending approval (Michigan, and Rhode Island) and one state’s CM application was denied (West Virginia). California is the only state to have confirmed implementing the Sect. 1115 Demonstration Waiver funding and has started to review evaluation data. The CM programs covered under Sect. 1115 Demonstration Waivers vary in substance targeted (e.g., stimulants, opioids), length of program (12–64 weeks), amount of incentives ($596–1092), and other characteristics (e.g. incentive delivery type, schedule of reinforcement). Conclusions Section 1115 Demonstration Waivers addressing SUDs with CM are still new but with the increase in waivers approved, states who wish to apply and receive funding can learn from the approved waivers.

Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study American Journal of Psychiatry This national retrospective cohort study found that veterans with stimul...

You are invited to join us for an exclusive look at the Peterson Health Technology Institute's (PHTI) latest assessment of virtual opioid use disorder (OUD) solutions. We will share our findings on th...

41% drop in risk of death seen in veterans who got incentives to stick with recovery from using stimulants like methamphetamine and cocaine, compared with those who didn’t

Background: Remote recruitment for human participant research is increasingly popular due to its speed, cost-effectiveness, and accessibility for participants. However, in some cases, it can be partic...

While AHSR 2025 may be on pause, our community isn’t! Join us for a special six-part webinar series running through Fall 2025 and Spring 2026 as we stay connected and dive into the most pressing topic...

Cannabis in Practice is a virtual web series for healthcare providers. Featuring multiple speakers on multiple topics.

The program addresses health inequities, such as a lack of access to care due to transportation or other issues.

The MI-ACRE Leadership team includes Allison Lin, M.D., M.S., Co-Director; Lara Coughlin, Ph.D., Co-Director; Erin E. Bonar, Ph.D., Director of Research Strategy; Anne Fernandez, Ph.D., Director of Cl...

The MI-ACRE Leadership team includes Allison Lin, M.D., M.S., Co-Director; Lara Coughlin, Ph.D., Co-Director; Erin E. Bonar, Ph.D., Director of Research Strategy; Anne Fernandez, Ph.D., Director of Cl...

Lewei Allison Lin, M.D., M.S. Even with effective care available, including medications and behavioral therapies, more than 80% of people living with substance use disorders (SUD) still don’t receive ...

Drug overdose deaths dropped in the United States in 2024 to the lowest levels seen in five years, according to a new CDC report published Wednesday morning.